Saegis Pharmaceuticals Appoints Genencor's Jean-Jacques Bienaime to Its Board of Directors
September 08 2004 - 9:00AM
PR Newswire (US)
Saegis Pharmaceuticals Appoints Genencor's Jean-Jacques Bienaime to
Its Board of Directors HALF MOON BAY, Calif., Sept. 8
/PRNewswire-FirstCall/ -- Saegis Pharmaceuticals, Inc., a
biopharmaceutical company focused on developing medicines that
protect and enhance memory and brain function, announced today the
appointment of Jean-Jacques Bienaime, chairman, CEO and president
of Genencor International, Inc. (NASDAQ:GCOR) to its Board of
Directors, increasing the total number of Board members to seven
(7). "We are delighted to have Jean-Jacques join our Board," said
Rodney Pearlman, Ph.D., President and CEO of Saegis. "His 25 years
of management experience in the biotech and pharmaceutical sector,
will help support Company growth as we progress our products
through the clinic. His unique depth of knowledge of this sector,
and, in particular his insights into corporate strategy, business
development and marketing, will be a valued contribution to the
Saegis Board." Bienaime joined Genencor in November 2002 as CEO and
president. Prior to Genencor, he served as chairman, CEO and
president of SangStat Medical Corporation (acquired by Genzyme)
where he managed the company's growth from $4 million to more than
$100 million, guiding SangStat to profitability. From 1992 to 1998
Bienaime served at Rhone-Poulenc Rorer Pharmaceuticals (now
Sanofi-Aventis) where in his last position of Senior Vice President
for Corporate Marketing and Business development he reoriented
RPR's strategic direction and focus around the company's key
therapeutic areas. In June 2004, Bienaime was appointed to the
Biotechnology Industry Organization (BIO) Board of Directors, while
also serving as a Board member at Aerogen Inc., NeurogesX and the
Fox Chase Cancer Center in Philadelphia. He holds a degree in
economics from Ecole Superieure de Commerce de Paris and an MBA
from The Wharton School at the University of Pennsylvania. "With a
lead product already in Phase II clinical studies for Alzheimer's
disease and a solid pipeline and platform technology in place, I
believe Saegis is poised to make an important contribution to the
treatment of cognitive dysfunction and central nervous system
diseases," said Bienaime. "I look forward to my role on the Board
and advising the company, as Saegis advances its promising products
through the clinic." About Saegis Pharmaceuticals Founded in 1999,
Saegis Pharmaceuticals is a pioneer in the development of medicines
that protect and enhance the function of the human mind. Through
licensing activity, development partnerships and internal discovery
programs, Saegis Pharmaceuticals is building a portfolio of
compounds with activity against a range of disorders of the brain
and central nervous system, including Alzheimer's disease, mild
cognitive impairment, and cognitive impairment associated with
schizophrenia. Currently the Company has three orally-available
small molecule compounds in clinical development, two of which have
already demonstrated efficacy and safety in humans. Privately held,
Saegis has received investment support from Versant Ventures,
Technology Partners, Sofinnova Ventures (U.S.), Sofinnova Partners
(Paris), Polaris Venture Partners, NeuroVentures, the Stanley
Medical Research Institute and Novartis Pharma AG. For more
information, visit http://www.saegispharma.com/ . Contacts: Saegis
Pharmaceuticals, Inc. Euro RSCG Life NRP Helen Jenkins Holli Kolkey
(650) 560-0210 x227 (858) 546-4811 DATASOURCE: Saegis
Pharmaceuticals, Inc. CONTACT: Helen Jenkins of Saegis
Pharmaceuticals, Inc., +1-650-560-0210, ext. 227, ; Holli Kolkey of
Euro RSCG Life NRP, +1-858-546-4811, , for Saegis Pharmaceuticals,
Inc. Web site: http://www.saegispharma.com/
Copyright
Genencor International (NASDAQ:GCOR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Genencor International (NASDAQ:GCOR)
Historical Stock Chart
From Oct 2023 to Oct 2024